

NATIONAL QUALITY FORUM

CONFERENCE CALL FOR THE PATIENT SAFETY COMPLICATIONS PROJECT: WORKGROUP A

December 2, 2011

Workgroup Members Present: Christina Michalek, PharmD, RPh, BSc; Gina Pugliese, MS, RN; Patricia Quigley, PhD, MPH; Tracy Wang, MPH

NQF Staff Present: Heidi Bossley, MBA, MSN; Akin Demehin, MPH; Andrew Lyzenga, MPP; Jessica Weber, MPH

Others Present: Noni Bodkin; Kyle Campbell; Maureen Dailey; Jeremy Gottlich; Sharon Hibay; Marcela Horvitz; Jill Manna; Soeren Mattke; Karen Nakana; Gary Rezak; Josep Rodrigues; Elizabeth Sloss; Almut Winterstein

WELCOME AND INTRODUCTIONS

Mr. Lyzenga welcomed Workgroup A to the conference call and explained the conference call goals:

- to create a shared understanding of the measures and a comfort level with the presentation of the measures at the Steering Committee meeting,
- to allow each group to review the full set of preliminary ratings and comments related to the measures, and
- to discuss any key issues or themes that emerged during the evaluation.

PROJECT UPDATE

The list of National Quality Forum (NQF) materials sent to the workgroup was reviewed, including the logistics memo, in preparation for the in-person Steering Committee meeting December 15-16, 2011. The group was advised that while measure stewards were invited to the call, they were not expected to address questions until the Steering Committee meeting, at which time their experts would be available to respond to the Steering Committee.

EVALUATION OF WORKGROUP A MEASURES

The group reviewed their preliminary ratings of the following assigned measures. They discussed both the ratings and the related comments.

- **0021:** Therapeutic monitoring: Annual monitoring for patients on persistent medications (*maintenance measure*)
- **0022:** Drugs to be avoided in the elderly: a. Patients who receive at least one drug to be avoided, b. Patients who receive at least two different drugs to be avoided (*maintenance measure*)
- **0419:** Documentation of Current Medications in the Medical Record (*maintenance measure*)
- **1729:** Polytherapy with Oral Antipsychotics

MEMBER AND PUBLIC COMMENT

There was no member or public comment.

NEXT STEPS

Mr. Lyzenga provided information about the role of the group members as lead discussants at the Steering Committee meeting on December 15-16. He described the meeting process and noted the measures from Phase I would be voted on for endorsement.